Human hepatocellular carcinoma (HCC) is the fifth most common cancer, yet it is among the most lethal cancers world wide because late detection and high frequency of tumor recurrence render current HCC therapy ineffective. We previously showed that mouse hepatocytes deficient (-/-) in the proliferation-specific Forkhead Box ml (Foxm1) transcription factor are highly resistant to developing Diethylnitrosamine (DEN)/Phenobarbital (PB) induced liver cancer and that FoxM1 transcriptional activity is inhibited by amino acids 26 to 44 from the ARF tumor suppressor. We also developed transgenic (TG) mice in which the Rosa26 promoter was used to drive ubiquitous expression of the human FoxM1b cDNA transgene. We have developed a new mouse model of aggressive metastatic liver cancer. After 33 weeks of DEN/PB exposure, ARF-/- Rosa-26 FoxM1b TG mouse livers are necrotic and develop aggressive HCC that metastasized to the lungs.
In Aim l, we propose to further characterize the proliferation, development and metastasis of this aggressive liver cancer and determine whether these hepatic tumors exhibit necrosis and activation of hepatic Kupffer and stellate cells. In preliminary studies, we pharmacologically reduced Foxm1 activity in HCC in vivo by subjecting DEN/PB treated wild type (WT) mice to daily injections of a cell penetrating ARF 24 to 46 peptide. After 4 weeks of this ARF peptide treatment. HCC regions display reduced cell proliferation and angiogenesis with a selective apoptosis of HCC. However, whether this ARF 26-44 peptide is also effective in preventing metastasis of liver cancer to the lung remains to be determined.
In Aim2, we propose to test the hypothesis that treatment of ARF -/- Rosa26 FoxM1b TG liver tumors with the cell penetrating ARF 26-44 peptide will inhibit HCC growth and lung metastasis. We have developed a new TG mouse line that conditionally expresses activated H-Ras in postnatal hepatocytes. We will use these mice to examine whether activated H-Ras stimulates progression of DEN induced liver tumors in both Rosa26-FoxM1b TG mice and ARF -/- Rosa26-FoxM1b TG mice and whether the cell penetrating ARF 26-44 peptide is an effective treatment to limit growth and progression of these liver tumors. Completion of the proposed studies will characterize new mouse models of aggressive metastatic liver cancer and determine whether the cell penetrating WT ARF 26-44 peptide is an effective treatment to prevent metastasis of liver cancer to the lung. These studies will facilitate development of a rational design for future translational research in the treatment of human liver cancer with this ARF peptide inhibitor of the FoxM1 transcription factor.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA124488-05
Application #
8018494
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Arya, Suresh
Project Start
2007-04-25
Project End
2014-01-31
Budget Start
2011-02-01
Budget End
2014-01-31
Support Year
5
Fiscal Year
2011
Total Cost
$277,864
Indirect Cost
Name
University of Illinois at Chicago
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Wang, Zebin; Zheng, Yu; Park, Hyun Jung et al. (2013) Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma. Mol Cancer Ther 12:759-67
Carr, Janai R; Kiefer, Megan M; Park, Hyun Jung et al. (2012) FoxM1 regulates mammary luminal cell fate. Cell Rep 1:715-29
Raychaudhuri, Pradip; Park, Hyun Jung (2011) FoxM1: a master regulator of tumor metastasis. Cancer Res 71:4329-33
Wang, Zebin; Park, Hyun Jung; Carr, Janai R et al. (2011) FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res 71:4292-302
Park, Hyun Jung; Gusarova, Galina; Wang, Zebin et al. (2011) Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med 3:21-34
Petrovic, Vladimir; Costa, Robert H; Lau, Lester F et al. (2010) Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol Ther 9:1008-16
Carr, Janai R; Park, Hyun Jung; Wang, Zebin et al. (2010) FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70:5054-63
Park, Hyun Jung; Carr, Janai R; Wang, Zebin et al. (2009) FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 28:2908-18
Chen, Yi-Ju; Dominguez-Brauer, Carmen; Wang, Zebin et al. (2009) A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem 284:30695-707
Park, H J; Wang, Z; Costa, R H et al. (2008) An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle. Oncogene 27:1696-704

Showing the most recent 10 out of 14 publications